Forest plots illustrate the mean difference in; (A) hospital stay, (B) ICU stay, (C) intubation time; with subgroup analysis. حسب Mohamed R. Abdelraouf (21501468)

CaCl₂ and MnCl₂ treatment significantly reduced Pol I occupancy on the rDNA template. حسب Abigail K. Huffines (20721555)

"…If the <i>p</i>-value < 0.05, that was deemed a significant difference between the two treatment groups and was indicated with either a green (increased occupancy) or black (decreased occupancy) line below the histogram for the CaCl₂ treated samples with respect to the untreated samples. …"

Comparing detector performance against increasing signal to noise ratios. حسب Bernd Porr (32394)

Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients. Metabolites were included based on an F-value > 2.5 and a p-value < 0.05. Metabolites marked with a single asterisk (*) were significant in both two-way ANOVA and ASCA, whereas those marked with double asterisks (**) were significant only in two-way ANOVA. Positive effect sizes indicate an increase in metabolite concentration between the compared groups, while negative values indicate a decrease. حسب Emir Matpan (21655811)

"…Positive effect sizes indicate an increase in metabolite concentration between the compared groups, while negative values indicate a decrease.…"

The mean number of the emerged <i>D. melanogaster</i> adults. Mean number (±SE) of emerged adults and average percentage (±SE) of the residual fertility at the different treatment... حسب Flavia Cerasti (21655934)

A) RT-qPCR analysis of <i>Yap</i>, <i>Taz</i>, and <i>Tead2</i> shows a significant decrease in transcript levels over postnatal stages from P0 to P28. حسب Heather L. Dingwall (14573796)

Difference in حسب Akihiro Kakimoto (343218)

الموضوعات:

Experimental protocol. حسب Akihiro Kakimoto (343218)

الموضوعات:

Relationship between the change in حسب Akihiro Kakimoto (343218)

الموضوعات:

Summary of post-treatment disease course measures from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. حسب Filip Stanicic (17808254)

الموضوعات:

Disease course measures after the PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from off-label medications clinical trials. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات: